MoonLake Immunotherapeutics
MLTX
114 hedge funds and large institutions have $2.99B invested in MoonLake Immunotherapeutics in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 37 reducing their positions, and 33 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 37
0.21% more ownership
Funds ownership: 99.09% → 99.3% (+0.21%)
9% less funds holding
Funds holding: 125 → 114 (-11)
15% less call options, than puts
Call options by funds: $22.9M | Put options by funds: $26.9M
15% less capital invested
Capital invested by funds: $3.53B → $2.99B (-$543M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
33% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$41.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$27.7M |
| 4 |
Holocene Advisors
New York
|
+$26.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$62.8M |
| 2 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$29M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$15.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$14.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.66M |
MLTX Hedge Fund Activity: Q1 2024 in Review
114 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2024, worth a combined $2.99B — down 15% from $3.53B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of MLTX and 22 opened new positions — a net loss of 11 holders — while 37 trimmed existing stakes and 44 added.
The largest buyer was Adage Capital Partners, adding an estimated $41.2M. The largest seller was Darwin Global Management, exiting entirely with an estimated $62.8M sold.
- 114 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2024, down from 125 in Q4 2023.
- Funds reported $2.99B of MoonLake Immunotherapeutics stock for Q1 2024, down 15% quarter-over-quarter.
- 22 funds opened new MoonLake Immunotherapeutics positions in Q1 2024 and 33 closed out, a net change of -11 holders.
- The largest MoonLake Immunotherapeutics buyer in Q1 2024 was Adage Capital Partners, an estimated $41.2M added.
- The largest MoonLake Immunotherapeutics seller in Q1 2024 was Darwin Global Management, an estimated $62.8M sold.
Based on aggregated 13F filings for Q1 2024.